RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY
Multiple myeloma (MM) usually responds to treatment but is incurable. The clinical course is characterised, in most patients, by a series of remissions and relapses. For younger patients, the initial treatment currently usually involves induction with the proteasome inhibitor bortezomib (BOR), alone...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2015-07-01
|
| Series: | European Medical Journal Hematology |
| Subjects: | |
| Online Access: | https://emj.emg-health.com/wp-content/uploads/sites/2/2018/02/RelapsedRefractory-Multiple-Myeloma-The-Current-State-of-Play1.pdf |